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Although EGFR is expressed at high levels in head and neck squamous cell carcinomas (HNSCCs) and mutations are extremely
rare,monotherapywithEGFRinhibitorshasshownlimitedsuccess.ThePI3kinase/Aktpathwayisresponsibleforcellularsurvival,
and inhibition of phosphatidylinositol (PI) synthesis has antiproliferative, anti-invasive, and antiangiogenesis eﬀects on HNSCC.
Molecular crosstalk has been observed between EGFR and IGF1R signaling through the PI3kinase/Akt pathway in HNSCC, as has
molecular crosstalk between the NFκB and STAT3 signaling pathways. Therefore, the combination of an EGFR antagonist with an
agent that inhibits the activation of both Akt and NFκB may overcome resistance to EGFR antagonists in HNSCC.
1.Introduction
head and neck squamous cell carcinoma (HNSCC) is the
sixth most common neoplasm worldwide, with approxi-
mately 600,000 patients newly diagnosed each year [1]. Over
the past 30 years, patients with recurrent and/or metastatic
HNSCC have had a poor prognosis [2, 3]. More than 50% of
newlydiagnosedpatientsdonotachievecompleteremission,
and approximately 10% relapse with metastasis to distant
organs [4]. Therefore, research focused on gaining a better
understanding of this disease and on the development of
novel treatment strategies is required.
Epidermalgrowthfactorreceptor(EGFR),aubiquitously
expressed transmembrane glycoprotein belonging to the
ErbB/HER family of receptor tyrosine kinases (TK), is
composed of an extracellular ligand-binding domain, a hy-
drophobic transmembrane segment, and an intracellular TK
domain. Upon ligand binding to EGFR, the latter undergoes
a conformational change that promotes homo- or hetero-
dimerization with other members of the ErbB/HER family
ofreceptors,followedbyautophosphorylationandactivation
of the TK domain [5]. Activation of EGFR leads to activation
of intracellular signaling pathways that regulate cell prolifer-
ation, invasion, angiogenesis, and metastasis.
EGFRisexpressedathighlevelsinthemajorityofepithe-
lial malignancies including HNSCC [6]. Elevated expression
of EGFR in HNSCC correlates with poor prognosis, and
EGFR has been a target of anticancer treatments due to its
critical roles in cell survival and proliferation [7]. Among
the tyrosine kinase inhibitors targeting EGFR that have been
approvedbytheUSFDAaregeﬁtinib,erlotinib,andlapatinib
[8]. These molecules are reversible competitors, competing
with adenosine triphosphate (ATP) for the tyrosine kinase
binding domain of EGFR. Inhibition of receptor activa-
tion inhibits downstream signaling pathways, resulting in
decreased cell proliferation and survival. EGFR signaling
activates a number of downstream eﬀectors including the
phosphatidylinositol-3-kinase (PI3K)/Akt pathway.
2. RareEGFRMutationsinHNSCC
Somatic mutations in the TK domain of the EGFR gene,
including in-frame deletions in exon 19 and the point
mutations L858, G719X, and L861Q, are associated with2 Journal of Oncology
increased sensitivity to EGFR tyrosine kinase inhibitors
(TKIs) and are present in 10∼30% of patients with nonsmall
cell lung carcinoma (NSCLC), depending on ethnic origin.
These mutant EGFRs selectively activate signal transduction
and activator of transcription (STAT) and Akt signaling
pathways, which promote cell survival.
However, they have no eﬀect on extracellular signal-
regulated kinase (ERK) signaling, which induces cell prolif-
eration. Furthermore, mutant EGFRs selectively transduce
survival signals, and inhibition of these signals may con-
tribute to the eﬃcacy of TKIs used to treat NSCLC [9].
However, molecular analysis of HNSCC tumor samples has
not revealed the same spectrum of mutations [10–12].
One important resistance mutation in EGFR is the
T790M missense mutation in the kinase domain, which
may contribute to TKI resistance in NSCLCs possessing the
L858Rpointmutation[13].UsingtheCycleavePCRmethod,
however, we failed to detect the T790M mutation in 86
HNSCC tumor samples [14].
3.Resistance toEGFRTKIs
EGFRTKIshavehadlimitedresultsinpatientswithHNSCC.
For example, a phase II trial of geﬁtinib in patients with
recurrent or metastatic HNSCC showed an overall response
rate of 11% [15]. Similarly, a study of erlotinib in patients
with recurrent and/or metastatic HNSCC showed a response
rate of 4% [16]. Four mechanisms have been proposed to
explain tumor resistance to EGFR TKIs.
3.1.RasMutations. K-ras mutationsmaycausetumorinsen-
sitivity to EGFR TKIs. Activating K-ras mutations may acti-
vatetheRas/mitogen-activatedproteinkinase(MAPK)path-
way independent of EGFR, thus inducing resistance to EGFR
TKIs [17]. H-ras mutations are more common than K-ras
mutations in HNSCC and may play an important role in
tumor resistance to EGFR-targeted therapies [18].
3.2. Epithelial-Mesenchymal Transition (EMT). EMT results
in changes in cell morphology and motility and is indicated
by increased expression of vimentin and claudins 4 and 7
and by decreased expression of E-cadherin. EMT has been
associated with geﬁtinib resistance in HNSCC [19].
3.3. Upregulation of Cyclin D1. Upregulation of cyclin D1
in HNSCC cell lines has been speciﬁcally associated with
resistance to geﬁtinib. Upregulation of cyclin D1 results
in the activation of cyclin D1-cyclin-dependent kinase 4
(CDK4),whichhyperphosphorylatesretinoblastomaprotein
(pRb) [20].
3.4. PI3Kinase/Akt Signaling as a Dominant Pathway. In-
creased expression of cortactin, a protein that increases the
formation of actin networks critical to cell motility and
receptor-mediated endocytosis, has been associated with
geﬁtinib resistance and increased metastasis in HNSCC [21].
Akt has been implicated in EMT by integrin-linked
kinase (ILK). The PI3K/Akt pathway not only regulates
the transcriptional activity of cyclin D1 but also increases
its accumulation by inactivating glycogen synthase kinase-3
(GSK3), an enzyme that targets cyclin D1 for proteasomal
degradation. Cortactin is thought to promote cancer cell
proliferation by activating Akt [21], suggesting that factors
related to resistance to EGFR TKIs are associated with the
PI3K/Akt pathway.
4.PI3K/Akt Pathway
In this section, we will explain the activation of the PI3K/
AKT pathway, its downstream eﬀectors, and the rationale for
targeting this pathway in HNSCC.
4.1. Activation of the PI3K/Akt Pathway. Signaling through
the PI3K/Akt pathway can be initiated by several mech-
anisms. Once activated, this pathway can be propagated
to various substrates, including mTOR, a master regulator
of protein translation. The PI3K/Akt pathway is initially
activated at the cell membrane, where the signal for
activation is propagated through class IA PI3K. Activa-
tion of PI3K can occur through tyrosine kinase growth
factor receptors such as EGFR and insulin-like growth
factor-1 receptor (IGF-1R), cell adhesion molecules such
as integrins, G-protein-coupled receptors (GPCRSs), and
oncogenes such as Ras. PI3K catalyzes the phosphoryla-
tion of the D3 position on phosphoinositides, generating
the biologically active moieties phosphatidylinositol-3,4,5-
triphosphate (PI(3,4,5)P3) and phosphatidylinositol-3,4-
bisphosphate(PI(3,4)P2).PI(3,4,5)P3bindstothepleckstrin
homology (PH) domains of 3 -phosphoinositide-dependent
kinase 1 (PDK-1) and Akt, resulting in the translocation
of these proteins to the cell membrane, where they are
subsequently activated. The tumor suppressor phosphatase
and tensin homolog deleted on chromosome ten (PTEN)
antagonizes PI3kinase by dephosphorylating PI(3,4,5)P3
and (PI(3,4)P2), thereby preventing the activation of Akt
and PDK-1. Akt exists as three structurally similar iso-
forms, Akt1, Akt2, and Akt3, which are expressed in most
tissues. Activation of Akt1 occurs through two crucial
phosphorylation events. The ﬁrst, catalyzed by PDK-1,
occurs at T308 in the catalytic domain of Akt1. Full
activation requires a subsequent phosphorylation at S473
in the hydrophobic motif of Akt1, a reaction mediated by
several kinases, including PDK-1, ILK, Akt itself, DNA-
dependent protein kinase, and mTOR; phosphorylation of
homologous residues in Akt2 and Akt3 occurs by the same
mechanism. Phosphorylation of Akt at S473 is controlled
by a recently described phosphatase, PH domain leucine-
rich repeat protein phosphatase (PHLPP), which has two
isoformsthatpreferentiallydecreasetheactivation ofspeciﬁc
Akt isoforms [22]. Ampliﬁcation of Akt1 has been described
in human gastric adenocarcinomas, and ampliﬁcation of
Akt2 has been described in ovarian, breast, and pancreatic
carcinomas [23, 24]. Akt mutations are rare, but somatic
mutations have been reported in the PH domain of Akt1 in
a small percentage of human breast, ovarian, and colorectal
cancers [25].Journal of Oncology 3
4.2. Downstream Substrates of Activated Akt. Akt recognizes
and phosphorylates the consensus sequence RXRXX (S/T)
when it is surrounded by hydrophobic residues. Since
this sequence is present in many proteins, Akt has many
substrates, many of which control key cellular processes
such as apoptosis, cell cycle progression, transcription,
and translation. For example, Akt phosphorylates proteins
in the FoxO subfamily of forkhead family transcription
factors, inhibiting the transcription of several proapoptotic
genes including Fas-L, IGF binding protein1 (IGFBP1),
and Bim. In addition, Akt can directly regulate apoptosis
by phosphorylating and inactivating proapoptotic proteins
such as BAD, which controls the release of cytochrome c
frommitochondria,andapoptosissignal-regulatingkinase-1
(ASK1), a mitogen-activated protein kinase kinase involved
in stress- and cytokine-induced cell death. In contrast,
Akt can phosphorylate IKK, which indirectly increases the
activity of nuclear factor kappa B (NF-κB) and stimulates
the transcription of prosurvival genes. Cell cycle progression
can also be aﬀected by Akt; inhibitory phosphorylation of
the cyclin-dependent kinase inhibitors p21 and p27, and
inhibition of GSK3 β by Akt, stimulates cellcycleprogression
by stabilizing cyclin D1 expression. A novel prosurvival Akt
substrate,proline-richAktsubstrateof40kDa(PRAS40),has
been described recently [26]. Phosphorylation of PRAS40 by
Akt attenuates its ability to inhibit mTORC1 kinase activity.
PRAS40 may be a speciﬁc substrate of Akt3 [27]. Therefore,
Akt inhibition may have pleiotropic eﬀects on cancer cells
that contribute to an antitumor response. The most studied
downstream substrate of Akt is the serine/threonine kinase
mammalian target of rapamycin (mTOR). Akt can directly
phosphorylate and activate mTOR, as well as indirectly
activating it by phosphorylating and inactivate tuberous
sclerosis complex 2 (TSC2), also called tuberin, which
normally inhibits mTOR through the GTP binding protein
Ras homolog enriched in brain (Rheb) [28]. When TSC2 is
inactivated by phosphorylation, the GTPase Rheb is main-
tained in its GTP-bound state, allowing increased activation
of mTOR [29]. mTOR exists in two complexes: the TORC1
complex, in which mTOR is bound to Raptor; and the
TORC2 complex, in which mTOR is bound to Rictor. In the
TORC1 complex, mTOR signals its downstream eﬀectors,
S6 kinase/ribosomal protein and 4EBP-1/eIF-4E, to control
protein translation [29]. mTOR is generally considered a
downstream substrate of Akt, but it can phosphorylate
Akt when bound to Rictor in TORC2 complexes [30],
resulting in positive feedback in the pathway. In addition, the
downstream mTOR eﬀector S6 kinase-1 (S6K1) can regulate
this pathway by catalyzing the inhibitory phosphorylation of
insulin receptor substrate (IRS) proteins. This prevents IRS
proteins from activating PI3kinase, thereby inhibiting the
activation of Akt [31].
4.3. Rationale for Targeting the PI3K/Akt Pathway. In addi-
tion to preclinical studies, clinical observations support the
targeting of the PI3K/Akt/mTOR pathway in human cancer
[32]. Immunohistochemical studies using antibodies that
recognize Akt phosphorylated at S473 have demonstrated
that activated Akt is detectable in cancers including head
a n dn e c kc a n c e r s[ 33]. Moreover, using antibodies against
S473 and T308, two sites of Akt phosphorylation, Akt
activation was shown to be selective for NSCLC versus
normal tissue, and phosphorylation of Akt at both sites
was shown to be a better predictor of poor prognosis
in NSCLC than phosphorylation at S473 alone [34]. In
addition, ampliﬁcation of Akt isoforms has been observed in
some cancers, albeit at a lower frequency. Another frequent
genetic event occurring in human cancer is loss of function
of the tumor suppressor PTEN, which normally suppresses
activation of the PI3K/Akt/mTOR pathway by functioning as
a lipid phosphatase. Loss of PTEN function in cancer can
occur through mutation, deletion, or epigenetic silencing.
In tumor types where PTEN mutations are rare, such as
lung cancer, epigenetic silencing can occur [35]. Mutation,
deletion, or epigenetic silencing of PTEN has been shown
to correlate with poor prognosis and reduced survival in
patients with various types of cancer [36], with loss of
PTEN being a common mechanism for activation of the
PI3K/Akt/mTOR pathway and poor prognosis. Activation of
PI3K has been described in human tumors that may result
from the ampliﬁcation, overexpression, or mutation of the
p110catalyticorp85regulatorysubunit.Ampliﬁcationofthe
3q26 chromosomal region, which contains the PI3KCA gene
that encodes the p110α catalytic subunit of PI3K, has been
observed in 40% of ovarian and 50% of cervical carcinomas
[37, 38]. Somatic mutations of this gene have been detected
in several cancer types, with mutant PI3K having increased
kinase activity relative to wild type [39]. Mutations in the
regulatory p85 subunit have also been detected. Any of the
alterations in individual components of the PI3 kinase/Akt
pathway would result in its activation, and activation of this
pathway has been reported to be among the most frequent
molecular alterations in tumors [39].
5. Inhibition of PI Synthesis in HNSCC
PIP2, a substrate of PI3K, may be synthesized from PI
by the PI4 and PI5 kinases. Therefore, inhibition of PI
metabolic pathway may be an important antitumor strategy.
Our laboratory has investigated three potential mechanisms




5.1. Antiproliferation. An imbalance between G1 cyclin and
cyclin-dependent kinase (CDK) inhibitors (CKIs) has been
reported to contribute to tumorigenesis and tumor progres-
sion. Cyclin D1/PRAD1 acts as a positive regulator of the cell
cycle by phosphorylating pRB (Rb protein) and by forming
a cyclin D1-CDK4 complex. Upon hyperphosphorylation by
CDKs, pRB releases E2F, a factor necessary for activating a
geneexpressionnetworkthatregulatesentryandprogression
through S phase.
CKIs can be classiﬁed into two groups: members of
the Ink4 family (p15, p16, p18, and p19), which are4 Journal of Oncology
incorporated into cyclin D/CDK4 and cyclin D/CDK6; and
members of the cip/kip family (p21, p27, and p57), which
are incorporated into cyclin D/CDK4 and cyclin E/CDK2.
Overexpression of cyclin D1 in HNSCC is an important
prognostic marker, predicting sensitivity to chemotherapy
and radiotherapy. Furthermore, imbalances between cyclin
D1 and its inhibitors (p16 and p27) may be critical in
the development of HNSCC. Strategies to block cyclin
D1 function have been studied extensively. For example,
introduction of an antisense cyclin D1 expression vector into
cells reduced their growth rate in vitro and decreased tjeor
tumorigenicity in athymic nude mice [40]. We previously
reported that inhibition of PI synthesis caused G1 arrest
of HNSCC, accompanied by decreased levels of cyclin D1,
cyclin E, and phosphorylated pRB [41].
5.2. Inhibition of MMP Production/Activity. Tumor metas-
tasis is a complex multistep process, including growth at
the primary site, entry into the circulation (intravasation),
adhesion to basement membranes (BMs) of target organs,
extravasation, and growth at secondary sites. The intravasa-
tion and extravasation processes involve degradation of the
BM by proteinases, normally MMPs. MMP-9/gelatinase B
and MMP-2/gelatinase A are speciﬁc for type IV collagen,
which acts as the backbone of BM, and therefore probably
play a major role in degrading the BM. In HNSCC, MMP-2
and MMP-9 are associated with metastatic potential. There-
fore, MMPs are attractive targets for therapy and many drugs
have been developed to prevent their extracellular matrix-
degrading activities during metastasis and angiogenesis. We
previously demonstrated that inhibition of PI synthesis
aﬀectstheproductionofMMP-2andMMP-9inHNSCCcell
lines [42].
5.3. Antiangiogenesis. Angiogenesis, the formation of new
blood vessels from preexisting capillaries or incorporat-
ing bone marrow-derived endothelial precursor cells into
growing vessels, is associated with the malignant phenotype
of cancer. Angiogenesis is also involved in other diseases,
including diabetic retinopathy, age-related macular degen-
eration, rheumatoid arthritis, psoriasis, atherosclerosis, and
restenosis [43]. Since tumor vascularity has been associated
with tumor aggressiveness in many tumor types, including
HNSCC, determining microvessel density in tumor tissues
may be useful in estimating patient prognosis. Inhibition
of angiogenesis can repress the growth rate of tumor cells
and lead to cell death resulting from reduced nutrition
and oxygen supply to the tumor. Upon binding to its
receptor Flk-1/KDR, vascular endothelial growth factor
(VEGF), which plays a major role in many angiogenic
processes, stimulates endothelial cell (EC) proliferation
through the phospholipase Cγ-protein kinase extracellular
signal-regulated kinase (C-ERK) pathway, but not via Ras
[44]. VEGF also stimulates EC migration through p38
mitogen-activated kinase (MAPK) independently of ERK
[45]. Therefore, these two major MAPK pathways may be
therapeutic targets for reduction of angiogenesis in HNSCC.
Most clinical trials of antiangiogenic agents have been
performed in patients with advanced disease who had
become resistant to conventional therapies. Phase III trials
of these agents have compared the eﬃcacy of standard
chemotherapyaloneandincombinationwithanexperimen-
tal angiogenesis inhibitor [46]. The results of some studies
were negative or unclear, but several recent clinical trials
have demonstrated a signiﬁcant clinical beneﬁt of VEGF
inhibition [47]. Sunitinib, a tyrosine kinase inhibitor of the
Flk-1/KDR receptor (VEGF receptor), and bevacizumab, a
monoclonal antibody against VEGF, have been approved by
the FDA [47]. Furthermore, we have demonstrated that the
inhibition of PI abrogated VEGF stimulation of the growth
and migration of human umbilical vein ECs through the
ERK-cyclin D1 and p38 pathways, respectively [48]. Since
increased expression of PI synthase is an early event in
HNSCC [49], inhibition of PI synthesis may be a potent
therapeutic strategy in patients with HNSCC [50].
6. Crosstalkbetweenthe IGF1Rand
EGFRPathways
6.1. Pathway Switching between EGFR and IGF1R. Growth
factor switching from one pathway to another may be an
adaptive mechanism, induced by blocking the dominant
growth factor receptor pathway. Blockade of EGFR signaling
inDU145andPC-3humanprostatecancercellshasfoundto
enhance the growth promoting eﬀects of the peptide growth
factor ligands basic ﬁbroblast growth factor (bFGF) and
IGF-1, respectively [51]. More recently, the EGFR-selective
tyrosine kinase inhibitor geﬁtinib has been shown to inhibit
the growth of EGFR-positive MCF-7-derived tamoxifen-
resistant breast cancer cells, an eﬀect that can be abrogated
by exposing the cells to non-EGF ligands such as heregulin-
β and IGF-II [52]. The reversal of the antitumor eﬀects of
geﬁtinib by IGF-II, acting through the IGF-1R, is accompa-
nied by reactivation of the previously reduced activity of Akt
andextracellular-regulatedkinase(ERK),withERKsignaling
contributing to the reestablishment of tumor cell growth.
Therefore, in the presence of a dominant growth pathway,
cancer cells are capable of responding to other growth
factors, compromising the antitumor activity of agents
designed speciﬁcally to inhibit EGFR. Importantly, blockade
of EGFR signaling frequently results in switching to the IGF-
1R pathway, a common mechanism used to promote resis-
tance to anti-EGFR treatment [53]. For example, geﬁtinib
initially inhibited the growth of the EGFR-positive DU145
prostate cancer cell line and of MCF-7-derived tamoxifen-
and fulvestrant-resistant breast cancer cell lines, but chronic
exposuretogeﬁtinibresultedinthedevelopmentofgeﬁtinib-
resistant variant sublines, all of which showed upregulation
of multiple IGF-1R signaling components when compared
with their parental cell lines [54]. This resulted in increased
production and elevated expression of the IGF-1R, ligand
IGF-II, increased activity of IGF-1R and increased levels of
Akt activity. In addition, although the A549 lung cancer
cell line is partially sensitive to geﬁtinib, chronic exposure
resulted in a resistant variant with increased activity ofJournal of Oncology 5
elements of the IGF-1R pathway. The importance of IGF-
1R signaling in cell lines with acquired geﬁtinib resistance
was supported by their increased dependency on IGF-1R
signaling and their greater sensitivity to growth inhibition by
IGF-1R-selective TKIs [54]. Therefore, the dominance of the
EGFR pathway in parental cells was replaced by an increased
use of the IGF-1R pathway in geﬁtinib resistant cells.
Growth factor pathway switching not only may result
from changes occurring during the development of acquired
resistance but also, critically, may occur rapidly and mod-
ulate initial sensitivity to EGFR-blockade, resulting in de
novo or intrinsic resistance to anti-EGFR agents such as
geﬁtinib. Indeed, although the EGFR and IGF-1R pathways
are classically regarded as separate entities, the overlapping
of downstream signal transduction molecules indicates that
these receptors can aﬀect each other’s signaling abilities,
although the precise mechanisms involved in this crosstalk
have not been fully elucidated. For example, geﬁtinib only
partially blocks EGFR activity in A549 lung cancer cells,
accompanied by a dramatic increase in the activity but not
the expression of IGF-1R. Moreover, in these cells IGF-1R
can transphosphorylate EGFR, maintaining EGFR activity in
the presence of geﬁtinib. Therefore, by enhancing IGF-1R
activity, geﬁtinib limits its own eﬃcacy in these cells. Inter-
estingly, it was observed that, in de novo geﬁtinib-resistant
LoVo colorectal cancer cells, which are defective in their
abilitytoproducematureIGF-1Randpredominantlyexpress
insulin receptor-isoform A (InsR-A), a close family member
of the IGF-1R, geﬁtinib enhances insulin receptor activity
and levels of downstream activated Akt [55]. Furthermore,
InsR can modulate and maintain EGFR phosphorylation
in these cells. Such rapid and dynamic interplay between
EGFR and IGF-1R or InsR may play an important role in
limiting the antitumor activity of geﬁtinib; partial and de
novo resistance to this inhibitor has been demonstrated in
A549 and LoVo cells, respectively.
6.2. Cotargeting the EGFR and IGF1R in HNSCC. Treatment
ofHNSCCcellsandxenograftswiththecombinationofanti-
bodies to IGF-1R and EGFR was more eﬀective than either
agent alone at reducing cancer cell growth [56], suggesting
a potential beneﬁt in the use of combined anti-tyrosine
kinase receptor directed therapies to treat HNSCC. Similarly,
the use of small molecules targeting these two pathways
suppressed the growth of HNSCC cells [57], as did the com-
bination of cetuximab with a PI3K inhibitor HNSCC [58].
7. Crosstalkbetweenthe NFκBa n d
STAT3SignalingPathways
Although EGFR activation has been found to lead to the
rapid phosphorylation of STAT3 on tyrosine 705 and the
subsequent activation of STAT3-dependent gene expression,
STAT3 tyrosine phosphorylation and the formation of active
STAT3 DNA-binding complexes were insensitive to EGFR
inhibition in many HNSCC cell lines [59]. Indeed, of
a representative panel of 10 HNSCC-derived cell lines,
9 showed increased tyrosine phosphorylation and STAT3
activity, but only 3 showed constitutive activation of EGFR
[59]. In searching for the mechanism responsible for the
EGFR-independent activation of STAT3 in HNSCC cells, the
activation of the gp130 cytokine receptor subunit was found
to promote the phosphorylation of STAT3 at tyrosine 705
through the activation of intracellular tyrosine kinases of the
JAK family. Surprisingly, gp130 activation was found to be
primarily initiated by IL-6, which is secreted by HNSCC cells
and binds to the cell surface in an autocrine fashion. These
ﬁndings suggest that the persistent activation of STAT3 in
HNSCC can result from the deregulation of EGFR activity
or from the EGF-independent autocrine activation of STAT3
by tumor-secreted cytokines. Furthermore, overexpression
of IL-6 in HNSCC cells was found to involve increased
transcriptionfromtheIL-6promoter,whichisdependenton
the presence of an intact NFκB response element located 63
to 75bp upstream of the IL-6 transcriptional initiation site.
Inhibition of NFκB resulted in the marked downregulation
of IL-6 mRNA and protein expression, concomitant with
the decreased release of other inﬂammatory cytokines, such
as IL-8, IL-10, granulocyte-macrophage colony-stimulating
factor (GM-CSF), and granulocyte colony-stimulating factor
(G-CSF). Surprisingly, the blockade of NFκB also resulted
in the drastic inhibition of constitutive STAT3 activity in
HNSCC cells, as reﬂected by the reduced tyrosine phos-
phorylation of STAT3. Interestingly, interfering with NFκB
function also prevented the autocrine/paracrine activation
o fS T A T 3i nH N S C Cc e l l s[ 60]. These ﬁndings support the
crosstalkbetweentheNFκBandtheSTAT3signalingsystems.
This crosstalk is initiated by the release of IL-6, resulting
from the NFκB-dependent activation of the IL-6 promoter,
and the subsequent tyrosine phosphorylation of STAT3 by
the autocrine/paracrine activation of IL-6 receptors in tumor
cells.
8.FutureProspects
Signaling of multiple receptor tyrosine kinases (RTKs) is
propagated through Akt. Therefore, simultaneous inhibition
of EGFR, as well as pathway components such as Akt or
mTOR, could circumvent the feedback activation observed
with either approach alone. The most extensive data con-
cerning proximal and distal signaling inhibition has been
observed by combining PI3K/Akt/mTOR pathway inhibitors
with EGFR antagonists. Several PI3K inhibitors can restore
cellular sensitivity to EGFR inhibitors. For example, the
selective pI3K inhibitor PX-866 and p110α were found
to abrogate geﬁtinib resistance in NSCLC xenografts [61].
Synergistic eﬀects of rapamycin and EGFR TKIs have been
observed in several in vitro systems, including glioblastoma
multiforme, prostate cancer, pancreatic cancer, squamous
cell carcinoma, renal cell carcinoma, leukemia, cervical
carcinoma, and NSCLC cell lines, as well as in some
xenografts [62–67]. The combination of rapamycin and
erlotinib showed resensitization and synergistic growth inhi-
bition in cell lines that were previously resistant to erlotinib
[64]. Moreover, the combination of rapamycin and the























Figure 1: Proposed mechanism for overcoming HNSCC resistance to EGFR antagonists using PI3kinase/Akt/mTOR and NFκB-IL6-STAT3
pathway inhibitors.
regression of lung tumors in transgenic mice possessing
the secondary resistance mutation T790M [68]. Addition
of the dual PI3K/mTOR inhibitor PI-103 to erlotinib was
necessary to induce growth arrest of human glioma cell
l i n e sw i t hm u t a n tP T E N[ 69], suggesting that activation
of the PI3K/Akt/mTOR pathway by EGFR-independent
mechanisms confers resistance to EGFR inhibitors, but
that this resistance can be overcome by the addition of
pathway inhibitors. Collectively, these ﬁndings suggest that
thecombinationofEGFRantagonistsandPI3K/Aktpathway
inhibitors may be beneﬁcial to patients with tumors resistant
to EGFR TKIs. These combinations, however, may be
insuﬃcient for the treatment of patients with HNSCC, due
to the crosstalk between the NFκB and STAT3 signaling
pathways, as described in Section 7,( Figure 1). In these
patients, the triple combination of EGFR antagonists with
PI3K/Akt/mTOR pathway inhibitors and NFκB-IL6-STAT3
pathway inhibitors may be eﬀective (Figure 1).
9. Conclusions
EGFR is expressed at a high level in HNSCC, but EGFR
inhibitor monotherapy has had limited success in patients
with these tumors. EGFR mutations are extremely rare in
HNSCC,whereasinhibitionofPIsynthesishasantiprolifera-
tive, anti-invasive, and antiangiogenesis eﬀects on HNSCCs.
The PI3K/Akt pathway is responsible for cellular survival
and there is molecular crosstalk between EGFR and IGF1R
signaling through PI3K/Akt in HNSCCs. Furthermore, there
is molecular crosstalk between the NFκB and STAT3 sig-
naling pathways. Therefore, combination therapy targeting
these three signaling pathways, PI3K/Akt, NFκB/STAT3,
and EGFR, may provide clinical beneﬁts for patients with
HNSCC.
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